A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples